AML1-ETO, a leukemia-associated fusion protein generated by the frequently occurred chromosome translocation t(8;21) in acute myeloid leukemia, was shown to exert dichotomous functions in leukemic cells, that is, growth arrest versus differentiation block. By the analysis of oligonucleotide microarray, AML1-ETO was shown to modulate the expressions of an impressive array of pro-and anti-apoptotic genes. Here, we investigate potential effects of the ecdysone inducible AML1-ETO expression on apoptosis of leukemic U937 cell line. We show that AML1-ETO significantly stabilizes death receptor Fas protein and increases proapoptotic Bak in addition to reducing Bcl-2 expression. Accordingly, inducible AML1-ETO expression is followed by apoptosis to a lower degree. Especially, AML1-ETO endows leukemic cells with the susceptibility to anti-Fas agonist antibody, ultraviolet light and camptothecin analog NSC606985-induced apoptosis with increased activation of caspase-3/8. Considering that apoptosis-enhancing effect of AML1-ETO would not be favorable to the leukemogenesis harboring the t(8;21) translocation, it must be overcome to fulfill their leukemogenic potential. Complementary to this prediction is that two AML1-ETO-carrying leukemic cells, Kasumi-1 and SKNO-1, present similar sensitivity to apoptosis induction with AML1-ETO-negative leukemic cells. Therefore, genetic and/or epigenetic screenings of apoptosis-related genes modulated by AML1-ETO deserve to be explored for understanding the mechanisms of AML1-ETO-induced leukemogenesis. Leukemia (2006) 20, 987-993.
Introduction
The chromosome translocation (8;21) (q22;q22) is one of the most frequently occurred chromosomal abnormalities associated with acute myeloid leukemia (AML). This translocation juxtaposes the AML1 gene on chromosome 21 with the ETO (eight-twenty-one) gene on chromosome 8 and generates the AML1-ETO fusion gene. 1 Its product AML1-ETO protein consists of the NH 2 -terminal portion of the wild-type AML1 protein, a member of the runt family of transcription factors, 2 fused in frame to the nearly full-length ETO protein. 1, 3 As widely documented, [4] [5] [6] AML1-ETO exerts the dominant negative effect on AML1-dependent transcriptional activation, mostly through interaction of its ETO moiety with nuclear corepressors N-CoR and Sin3A that recruit the histone deacetylases, and lead to a lower level of histone acetylation and less-accessible chromatin.
On the other hand, AML1-ETO also regulates expressions of a number of specific target genes that are not normally regulated by AML1. 7 The substantial reports showed that ectopic expression of the AML1-ETO gene inhibits the differentiation of leukemic cells towards granulocytic, monocytic or erythroid cells, as reviewed by Peterson and Zhang. 3 In agreement, AML1-ETO suppression by small interfering RNAs promotes myeloid differentiation in t(8;21)-positive leukemic cells. 8 Contrary to this leukemogenic activity, inducible AML1-ETO expression by tetracycline inducible system induces growth arrest in leukemic U937 cell line, which eventually undergoes apoptosis with the reduced expression of anti-apoptotic Bcl-2 gene. 9 Using global gene expression profile analyses by oligonucleotide microarray, some groups have recently provided evidences that AML1-ETO has impacts on the expression of many proand anti-apoptotic genes in a murine myeloid progenitor L-G cell line 10 and human leukemic U937 cell line. 11 On the basis of these interesting findings, here we investigate the potential effects of AML1-ETO on leukemic cell apoptosis, using leukemic cell line U937 with inducible expression of the AML1-ETO gene by the ecdysone inducible system as an in vitro model. Our results indicate that AML1-ETO induction makes leukemic cells prone to both extrinsic and intrinsic apoptosis, which is accompanied with the increased death receptor Fas and proapoptotic Bak proteins in addition to reducing Bcl-2.
Materials and methods

Reagents and cell lines
Promonocytic leukemia U937 cell line and U937-A/E 9/14/18 cells, which had been described previously, 12, 13 as well as leukemic Kasumi-1, SKNO-1, NB4, HL60, KG1a cell lines, were cultured in RPMI-1640 medium (Sigma, St Louis, MO, USA) supplemented with 10% heat-inactivated fetal calf serum (Gibco BRL, Gaithersburg, ML, USA) in 5% CO 2 /95% air humidified atmosphere at 371C. Of note, 10 ng/ml of granulocyte-macrophage colony stimulating factor(GM-CSF) was added into medium for culturing SKNO-1 cells. For the induction of AML1-ETO expression in U937-A/E9/14/18 cells, 5 mM ponasterone A (Invitrogen, Groningen, The Netherlands) was added to the medium and Western blot was performed to confirm AML1-ETO expression. For experiments, cells were originally seeded at 2-3 Â 10 5 cells/ml and cell viability was determined by the trypan-blue exclusion assay. NSC606985 (kindly provided by National Cancer Institute Anticancer Drug Screen standard agent database) was dissolved in double distilled water as a 25 mM stock solution. For induction of apoptosis by ultraviolet light (UV) irradiation, the cells were exposed to a germicidal lamp providing predominantly 254-nm UV-C light (Philips TUV G30T8 30 W bulb).
Flow cytometry analysis
The mitochondrial transmembrane potentials (DCm) was detected by Rhodamine 123 (Rh123, Sigma, St Louis, MO, USA) staining as described previously.
14 Annexin-V assay was performed by the ApoAlert Annexin-V kit according to manufacturer's instructions (Clontech, Palo Alto, CA, USA). For the assay of Fas protein on the cell surface, 5 Â 10 5 cells were labeled with mouse monoclonal anti-Fas IgM antibody, CH11 (Upstate, Waltham, MA, USA) for 1 h at 41C, and mouse preimmune IgM (Sigma, St Louis, MO, USA) was used as a control. Afterwards, cells were stained with goat anti-mouse IgM-FITC (Santa Cruz, CA, USA) for additional 1 h at 41C. Fluorescent intensities of all dyes were determined by flow cytometry (Beckman Coulter, Miami, FL, USA).
Reverse transcription-polymerase chain reaction
Total RNAs were extracted from cells by TRIzol reagent (Gibco BRL, Gaithersburg, ML, USA) and RT was performed by TaKaRa RNA PCR kit (Takara, Dalian, China) following manufacturer's instructions. For real-time quantitative reverse transcriptionpolymerase chain reaction (RT-PCR), the following specific oligonucleotide primers were used for Bak (sense, 5 0 -GAA CAG GAG GCT GAA GGG GT-3 0 , antisense, 5 0 -TCA GGC CAT GCT GGT AGA CG-3 0 ) and Fas (sense, 5 0 -CAC TAT TGC TGG AGT CAT G-3 0 , antisense, 5 0 -CTG AGT CAC TAG TAA TGT CC-3 0 ) with b-actin as internal control (sense, 5 0 -CAT CCT CAC CCT GAA GTA CCC-3 0 , antisense, 5 0 -AGC CTG GAT AGC AAC GTA CAT G-3 0 ). Real-time RT-PCR was performed and data were analyzed as reported previously. 15 For semi-quantitative RT-PCR, the same primers for Bak and Fas as described above were used. PCR reactions to amplify Bak/Fas and cyclophilin B (Cyp B, sense, 5 0 -CGG TGG ACC ACG AAG AGT TAA C-3 0 , antisense, 5 0 -CCA ACG CTT TTA GAG GCA GAT C-3 0 ) were performed in a single tube using the Eppendorf Mastercycler (Eppendorf AG, Hamburg, Germany). Polymerase chain reaction products were analyzed on a 1% agarose gel. All RT-PCR were repeated at least three times.
Western blot
Protein extracts were equally loaded on 10-12% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and electrophoretically transferred to Immobilon-PVDF membranes Cycloheximide-inhibiting test U937-A/E9/14/18 cells were treated with and without 5 mM ponasterone A for 48 h. Then, cycloheximide (Sigma, St Louis, MO, USA) was added to the culture medium at a final concentration of 10 mg/ml for the indicated times.
Statistical analysis
The Student's t-test was used to compare the difference between two different groups. A value of Po0.05 was considered to be statistically significant.
Results
U937-
A/E 9/14/18 subclone was generated by introducing ecdysone-inducible two vector system to conditionally express the AML1-ETO protein into human leukemic U937 cells, as reported previously. 13 In principle, a heterodimeric hormone receptor encoded by the first vector pVgRXR is constitutively expressed and become activated through binding with its ligand ponasterone A, a synthetic ecdysone derivative. The activated receptor binds to response elements in the promotor region provided by the second vector pINDAML1-ETO, thereby transcriptionally activating the expression of AML1-ETO fusion gene. As shown in Figure 1a , when U937-A/E 9/14/18 cells were treated with 5 mM ponasterone A, AML1-ETO expression was induced in a time-dependent manner. Although previous cDNA microarray analyses and differential display had identified some AML1-ETO-regulated apoptosis-related genes, 10, 11 we also examined the potential effects of AML1-ETO expression on apoptosis-related genes in U937-A/E 9/14/18 cells by cDNA microarray (our unpublished data). We, here, show for the first time that AML1-ETO significantly increased the Fas protein level in U937 cells, as evidenced by Western blot (Figure 1b ) and flow cytometry (Figure 1c ), but it did not alter the Fas mRNA level (Figure 1d ). Furthermore, cycloheximide-inhibiting test showed that AML1-ETO induction significantly inhibited degradation of Fas protein in the presence of protein synthesis inhibition by cycloheximide. As can be seen in Figure 1e , Fas protein still existed in the disappearance of AML1-ETO protein at 24 h after cycloheximide treatement.
We also showed that treatment with ponasterone A for 48 and 72 h, to induce AML1-ETO expression, also elevated proapoptotic Bak protein (right panel, Figure 2a ) with mild increase of Bak mRNA (Figure 2b/c). During 24 h tested after cycloheximide treatment, Bak protein remained stable regardless of the presence or absence of AML1-ETO protein (Figure 1e ), proposing that Bak protein had a longer half life. It is worthy to note that the same ponasterone A treatment in U937 cells did not produce similar alterations in these proteins (left panel, Figure 2a ), indicating the specificity of AML1-ETO actions. Moreover, AML1-ETO induction by ponasterone A treatment for 72 h also reduced Bcl-2 protein (Figure 2a ), consistent with a previous report. 9 However, AML1-ETO induction failed to significantly change Mcl-1, Bax and Bid protein levels as determined by immunoblots (Figure 2a) .
The effect of inducible expression of AML1-ETO on induction of apoptosis was then analyzed in U937-A/E 9/14/18 cells. We demonstrated that, after ponasterone A treatment for 2-3 days in U937-A/E 9/14/18 cells but not in wild-type U937 cells, apoptotic cells was statistically significantly increased, although to a lower degree, as evidenced by the mitochondrial DCm and annexin-V assay ( Figure 3 and Figure 4a /b). This result suggests that AML1-ETO induction is followed by apoptosis, which was consistent to a report from Burel et al.
In the next phase of analysis, we studied whether induction of AML1-ETO expression changes the sensitivity of leukemic cells to apoptosis. Towards this end, U937-A/E 9/14/18 cells, with its parental U937 cells as controls, were pretreated with 5 mM of ponasterone A for 48 h to induce AML1-ETO protein (Figure 1b) , and then, cells were exposed to 50 ng/ml of anti-Fas agonist In contrast, the same CH11 treatment failed to induce apoptosis in wild-type U937 cells regardless of the presence or absence of ponasterone A treatment (Figure 3b ). Fas stimulation has been reported to cause the concentration-dependent decrease of the DCm in many types of cells, although its mechanism remained controversial. [16] [17] [18] Thus, we also tested DCm upon activation of Fas receptor by CH11. As seen in Figure 3c , CH11-induced DCm loss was also enhanced by AML1-ETO expression in U937-A/E 9/14/18 cells. These results suggest that inducible AML1-ETO expression, but not ponasterone A itself, makes U937 cells susceptible to death receptor Fas-induced apoptosis.
Besides the extrinsic mode of apoptosis that is initiated by the transmembrane death receptors such as Fas, apoptosis is also mediated by the intrinsic mitochondrial pathway, which is triggered by various stimuli, including UV light and genotoxic agents that cause DNA damage. 19, 20 To test the effects of AML1-ETO expression on mitochondria-mediated apoptosis, NSC606985, a rarely studied camptothecin analog, 14 and UV light at a dose of 400 J/m 2 were used. Consistent with our previous report, 14 treatment of U937 cells with 50 nM of NSC606985 for 24 h did not significantly induce apoptosis. Following ponasterone A pretreatment for 48 h, however, the addition of NSC606985 significantly induced the DCm collapse and cell apoptosis in U937-A/E 9/14/18, but not in wild-type U937 cells (Figure 4a) . Similarly, UV-induced DCm loss and apoptosis were remarkably enhanced by AML1-ETO expression in U937-A/E 9/14/18 cells in a time-dependent manner (Figure 4b and c) . 
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Caspases are critical executioners of apoptosis induced by most apoptosis-inducing factors including death receptor, UV and NSC606985. 14, 21, 22 In order to further confirm the effects of AML1-ETO expression on enhancing apoptosis, changes in caspase-3 and -8 proteins were analyzed in U937-A/E 9/14/18 cells treated with CH11 (50 ng/ml) or NSC606985 (50 nM) in the presence or absence of ponasterone A pretreatment for 48 h. As shown in Figure 5a , both CH11 and NSC606985 significantly activated caspase-3 in the presence of AML1-ETO expression, as indicated by the appearance of two active fragments 17/19-kDa of caspase-3 on the blot. Of great interests, AML1-ETO expression also significantly enhanced these two agents-induced activation of caspase-8, as demonstrated by the increase in two active fragments (40 and 24 kDa) of caspase-8. Of note, AML1-ETO failed to increase pro-caspase-8 protein, and CH11 and NSC606985 did not affect AML1-ETO-induced upregulation of Bak protein (Figure 5a) .
The enhancing apoptosis would not be favorable to the leukemogenesis harboring the t(8;21) translocation. On the basis of this view, we predicted that AML1-ETO-induced apoptosisenhanced effect must be overcome so as to fulfill the leukemogenic potential of AML1-ETO fusion gene. Therefore, we also investigated the response of Kasumi-1 and SKNO-1 cells, two AML cell line from M2b-type AML with t(8;21), 23, 24 as well as other AML1-ETO-minus leukemic cell lines U937, HL60, KG1a and NB4 cells to CH11, UV and NSC606985-induced apoptosis. Our results showed that Kasumi-1 and SKNO-1 cells had similar sensitivity to CH11, UV and NSC606985-induced apoptosis with other four cell lines tested, except more sensitivity of NB4 cells to NSC606985-induced apoptosis (Figure 5b ). It should be noted that Kasumi-1 and especially SKNO-1 cells expressed lower levels of AML1-ETO protein than U937-A/E 9/14/18 cells which were incubated with 5 mM ponasterone A for 48 h (Figure 5b ).
Discussion
As well documented, there are two major pathways to initiate cell apoptosis: the extrinsic pathway and the intrinsic pathway. 25, 26 The ligation of transmembrane death receptors (such as Fas)-initiated extrinsic apoptosis is promoted by activation of caspase-8 through adapter proteins (such as Fas-associated death domain, FADD). The intrinsic mitochondrial pathway is activated by disruption of the DCm and then the activation of caspase-9 through the release of mitochondrial proteins such as cytochrome c. These apoptotic pathways can be stimulated by various stimuli, including UV light, genotoxic agents that cause DNA damage and others. 21, 22 Thereby, caspases-8/9 initiate the apoptotic caspase cascade, in which caspase-3 is the major effector. 27 As described recently, 14 NSC606985 induces AML cell apoptosis via PKCd-triggered DCm collapse and caspase-3 AML1-ETO and leukemic cell apoptosis Y Lu et al activation, while UV light, a well-established DNA mutagen, induces apoptosis through both the intrinsic and extrinsic pathways. 22 Consistent with the previous report, 9 we showed that AML1-ETO induction in U937 cells was followed by apoptosis, although to a lower degree. In the presence of AML1-ETO induction, more intriguingly, apoptosis induced by Fas agonist, NSC606985 or UV light was greatly enhanced in U937 cells, as evidenced by the enhanced caspases-8/3 activation and increased DCm collapse and annexin-V þ cells. These experiments strongly propose that inducible AML1-ETO expression significantly increases cell sensitivity to both intrinsic and extrinsic mode-mediated apoptosis.
Apoptosis is a cellular suicide route that allows for the selective removal of superfluous and potentially dangerous cells as well as for tissue remodeling and homeostasis. Thus, apoptotic process is closely regulated by multicellular organisms. 28, 29 It was previously reported that the AML1-ETO fusion protein was able to induce anti-apoptotic Bcl-2 expression in vitro, 30 while Burel et al. 9 and our present study showed an AML1-ETO-induced decrease in Bcl-2 protein. In agreement, primary AML cells with t(8;21) chromosomal translocation generally have low level of Bcl-2 protein relative to normal bone marrow-derived myeloid cells and to AML samples with other simple karyotypic abnormalities. 31 In spite of these controversies about the action of AML1-ETO on Bcl-2 expression, high throughout analyses of gene expression profiles by microarray proposed that inducible AML1-ETO expression modulates the expression of many apoptosis-related genes. For example, Alcalay et al. 11 reported that AML1-ETO regulated the expressions of 17 apoptosis-inducing genes (such as Bcl2-like 11, Bid, N-myc downstream regulated gene 1 (NDRG1), caspase-8 and Fas associated factor 1) and 9 apoptosis-inhibiting genes (such as Mcl-1, for details, see Alcalay et al.
11
). However, we did not find that AML1-ETO modulated caspase-8, Bid and Mcl-1 on their protein levels. On the contrary, AML1-ETO increased the expression of Bak protein, a pro-apoptotic member of the Bcl-2 family that plays an important role in regulating mitochondrial membrane permeability during apoptosis. 32 More intriguingly, we demonstrated for the first time that inducible AML1-ETO expression significantly increased and stabilized death receptor Fas protein. These results suggest that in addition to modulate gene expression as a transcriptional factor, AML1-ETO probably impacts translational and/or posttranslational processes of some proteins such as Fas protein, which deserves to be further investigated. In total, the effect of AML1-ETO on enhancing cell susceptibility to apoptosis involves its impacts on transcriptional regulatory networks of apoptosis-regulated gene at the mRNA and/or protein levels. The exact importance of these modulated genes in AML1-ETO-enhanced apoptosis remained to be investigated, one by one, through siRNA or other tools.
The enhancement of apoptosis would antagonize the generation of leukemia harboring the t(8;21) translocation. Therefore, it was predicted that AML1-ETO-induced apoptosis-related effects must be overcome prior to fulfilling the leukemogenic potential of AML1-ETO fusion gene. The t(8;21) is the sole cytogenetic abnormality in the majority of AML1-ETO-positive AML cases, suggesting that AML1-ETO plays a critical role both in the distinctive phenotype and in the establishment of the leukemic clone. However, various models developed to study AML1-ETO function in mice failed to reliably produce overt leukemia in mice, as reviewed in Peterson and Zhang. 3 Furthermore, AML1-ETO transcripts were also presented during normal fetal development. 33 These data strongly propose that AML1-ETOassociated leukemogenesis requires a secondary event or 'hit' for AML1-ETO-positive cells to adopt leukemogenic behavior. 34 Recently, Warner et al. 35 provided the direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. We predicted that AML1-ETO-modulated apoptosis-regulated genes and/or proteins might become the targets for secondary 'hit' that contributes to pathogenesis of AML1-ETO-related leukemia. Here, we showed that Kasumi-1 and SKNO-1 cells with endogenously expressed AML1-ETO protein appeared to present similar sensitivity to CH11, UV and NSC606985-induced apoptosis with several AML-ETO-minus leukemic cell lines. Kasumi-1 and especially SKNO-1 cells expressed lower levels of AML1-ETO protein than U937-A/E 9/14/18 cells incubated with 5 mM ponasterone 
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A for 48 h, which made it difficult to exclude the possibility that apoptosis-enhancing effect of AML1-ETO induction is due to higher AML1-ETO protein level. However, it was rational to extrapolate that some genetic or/and epigenetic alterations of apoptosis-related genes have appeared in these AML1-ETOpositive AML cells, which overcome the apoptosis-enhanced effect of AML1-ETO. Therefore, the screening of apoptosisrelated genes modulated by AML1-ETO deserves to be explored.
